Aysegul Ozen
Cited by
Cited by
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors
KP Romano, A Ali, C Aydin, D Soumana, A Özen, LM Deveau, C Silver, ...
PLoS pathogens 8 (7), e1002832, 2012
Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2
SA Foster, DM Whalen, A Özen, MJ Wongchenko, JP Yin, I Yen, ...
Cancer cell 29 (4), 477-493, 2016
Molecular basis for drug resistance in HIV-1 protease
A Ali, RM Bandaranayake, Y Cai, NM King, M Kolli, S Mittal, JF Murzycki, ...
Viruses 2 (11), 2509-2535, 2010
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance
MNL Nalam, A Ali, MD Altman, GSKK Reddy, S Chellappan, V Kairys, ...
Journal of virology 84 (10), 5368-5378, 2010
Extreme entropy–enthalpy compensation in a drug-resistant variant of HIV-1 protease
NM King, M Prabu-Jeyabalan, RM Bandaranayake, MNL Nalam, ...
ACS chemical biology 7 (9), 1536-1546, 2012
Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope
A Özen, T Haliloğlu, CA Schiffer
Journal of molecular biology 410 (4), 726-744, 2011
Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance
A Ali, C Aydin, R Gildemeister, KP Romano, H Cao, A Özen, D Soumana, ...
ACS chemical biology 8 (7), 1469-1478, 2013
Clusters of isoleucine, leucine, and valine side chains define cores of stability in high‐energy states of globular proteins: Sequence determinants of structure and stability
SV Kathuria, YH Chan, RP Nobrega, A Özen, CR Matthews
Protein Science 25 (3), 662-675, 2016
Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease
SK Lee, M Potempa, M Kolli, A Özen, CA Schiffer, R Swanstrom
Journal of Biological Chemistry 287 (16), 13279-13290, 2012
Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer
MS Eno, JD Brubaker, JE Campbell, C De Savi, TJ Guzi, BD Williams, ...
Journal of medicinal chemistry 65 (14), 9662-9677, 2022
Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease
A Özen, KH Lin, N Kurt Yilmaz, CA Schiffer
Proceedings of the National Academy of Sciences 111 (45), 15993-15998, 2014
Improving the resistance profile of hepatitis C NS3/4A inhibitors: Dynamic substrate envelope guided design
A Özen, W Sherman, CA Schiffer
Journal of chemical theory and computation 9 (12), 5693-5705, 2013
Machine learning integration for predicting the effect of single amino acid substitutions on protein stability
A Özen, M Gönen, E Alpaydın, T Haliloğlu
BMC Structural Biology 9, 1-17, 2009
HIV-1 protease and substrate coevolution validates the substrate envelope as the substrate recognition pattern
A Özen, T Haliloğlu, CA Schiffer
Journal of Chemical Theory and Computation 8 (2), 703-714, 2012
HIV-1 protease-substrate coevolution in nelfinavir resistance
M Kolli, A Özen, N Kurt-Yilmaz, CA Schiffer
Journal of virology 88 (13), 7145-7154, 2014
Molecular basis for differential patterns of drug resistance in influenza N1 and N2 neuraminidase
KL Prachanronarong, A Özen, KM Thayer, LS Yilmaz, KB Zeldovich, ...
Journal of chemical theory and computation 12 (12), 6098-6108, 2016
Selectively modulating conformational states of USP7 catalytic domain for activation
A Özen, L Rouge, C Bashore, BR Hearn, NJ Skelton, EC Dueber
Structure 26 (1), 72-84. e7, 2018
Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors
A Özen, K Prachanronarong, AN Matthew, DI Soumana, CA Schiffer
Critical reviews in biochemistry and molecular biology 54 (1), 11-26, 2019
Drug‐resistant HIV‐1 protease regains functional dynamics through cleavage site coevolution
N Özer, A Özen, CA Schiffer, T Haliloğlu
Evolutionary applications 8 (2), 185-198, 2015
Resistance from Afar: Distal Mutation V36M Allosterically Modulates the Active Site to Accentuate Drug Resistance in HCV NS3/4A Protease
A Özen, KH Lin, KP Romano, D Tavella, A Newton, CJ Petropoulos, ...
bioRxiv, 452284, 2018
The system can't perform the operation now. Try again later.
Articles 1–20